TWI488627B - 左氧氟沙星或其鹽或該等之溶劑合物之用途 - Google Patents

左氧氟沙星或其鹽或該等之溶劑合物之用途 Download PDF

Info

Publication number
TWI488627B
TWI488627B TW099146206A TW99146206A TWI488627B TW I488627 B TWI488627 B TW I488627B TW 099146206 A TW099146206 A TW 099146206A TW 99146206 A TW99146206 A TW 99146206A TW I488627 B TWI488627 B TW I488627B
Authority
TW
Taiwan
Prior art keywords
levofloxacin
eye
eye drops
genus
conjunctivitis
Prior art date
Application number
TW099146206A
Other languages
English (en)
Chinese (zh)
Other versions
TW201129364A (en
Inventor
長野敬
阪中浩二
中村雅胤
河津剛一
伊吹肇
坂本佳代子
Original Assignee
參天製藥股份有限公司
第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 參天製藥股份有限公司, 第一三共股份有限公司 filed Critical 參天製藥股份有限公司
Publication of TW201129364A publication Critical patent/TW201129364A/zh
Application granted granted Critical
Publication of TWI488627B publication Critical patent/TWI488627B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW099146206A 2010-02-25 2010-12-28 左氧氟沙星或其鹽或該等之溶劑合物之用途 TWI488627B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010040281 2010-02-25

Publications (2)

Publication Number Publication Date
TW201129364A TW201129364A (en) 2011-09-01
TWI488627B true TWI488627B (zh) 2015-06-21

Family

ID=44506417

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099146206A TWI488627B (zh) 2010-02-25 2010-12-28 左氧氟沙星或其鹽或該等之溶劑合物之用途

Country Status (16)

Country Link
US (1) US20120316158A1 (enExample)
EP (1) EP2540299B1 (enExample)
JP (3) JP5600056B2 (enExample)
KR (2) KR20130043611A (enExample)
CN (1) CN102770141A (enExample)
BR (1) BR112012021247A2 (enExample)
CA (1) CA2791190C (enExample)
EA (1) EA201290827A1 (enExample)
ES (1) ES2568647T3 (enExample)
MX (1) MX349603B (enExample)
MY (1) MY183483A (enExample)
NZ (1) NZ602126A (enExample)
PH (2) PH12012501674A1 (enExample)
SG (1) SG183427A1 (enExample)
TW (1) TWI488627B (enExample)
WO (1) WO2011104981A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791190C (en) * 2010-02-25 2017-12-12 Santen Pharmaceutical Co., Ltd. Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof
CN103550144B (zh) * 2013-10-25 2015-10-14 深圳朗欧医药集团有限公司 盐酸左氧氟沙星组合物注射液及其制备方法
JP6363833B2 (ja) * 2013-11-22 2018-07-25 ナノシータ株式会社 薄膜状高分子構造体
CN104606198A (zh) * 2015-01-09 2015-05-13 周元铎 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038722B2 (ja) 1989-06-23 2000-05-08 日本電気株式会社 接合型電界効果トランジスタ
JP3192290B2 (ja) 1993-08-04 2001-07-23 カネボウ株式会社 ポリエステル製耐熱ボトル
US7629458B2 (en) * 2001-10-03 2009-12-08 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and hemihydrate thereof
US7169792B2 (en) * 2001-11-30 2007-01-30 Lg Life Sciences Ltd. Method of treating bacterial infections using gemifloxacin or a salt thereof and a β-lactam antibiotic
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
JP2009526003A (ja) * 2006-02-10 2009-07-16 パーリ・ファルマ・ゲーエムベーハー 吸入療法用噴霧状抗生物質
WO2008005276A2 (en) * 2006-06-30 2008-01-10 Directcontact Llc Growth factor delivery system containing antimicrobial agents
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
CA2791190C (en) * 2010-02-25 2017-12-12 Santen Pharmaceutical Co., Ltd. Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use

Also Published As

Publication number Publication date
PH12012501674A1 (en) 2012-11-05
PH12016501747A1 (en) 2019-02-11
WO2011104981A1 (ja) 2011-09-01
US20120316158A1 (en) 2012-12-13
SG183427A1 (en) 2012-09-27
JP5600056B2 (ja) 2014-10-01
JP2013241464A (ja) 2013-12-05
EP2540299A4 (en) 2013-07-24
MX349603B (es) 2017-08-03
PH12016501747B1 (en) 2022-06-22
CA2791190C (en) 2017-12-12
JP5674882B2 (ja) 2015-02-25
JP2011195564A (ja) 2011-10-06
EP2540299A1 (en) 2013-01-02
BR112012021247A2 (pt) 2018-04-03
CN102770141A (zh) 2012-11-07
MY183483A (en) 2021-02-20
CA2791190A1 (en) 2011-09-01
AU2010346703A1 (en) 2012-09-20
JP2012162532A (ja) 2012-08-30
EP2540299B1 (en) 2016-04-13
NZ602126A (en) 2013-10-25
TW201129364A (en) 2011-09-01
HK1177887A1 (en) 2013-08-30
EA201290827A1 (ru) 2013-03-29
KR20130043611A (ko) 2013-04-30
KR20170070265A (ko) 2017-06-21
ES2568647T3 (es) 2016-05-03
MX2012009844A (es) 2012-09-21

Similar Documents

Publication Publication Date Title
MX2014011468A (es) Gotas para los ojos que contienen diquafosol.
CA2987783A1 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
US20110294768A1 (en) Ophthalmic Suspension for Ocular Use
JP5674882B2 (ja) レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤
JP2024129025A (ja) リファマイシンの眼科用組成物およびその使用
Marchino et al. Acute-onset endophthalmitis caused by alloiococcus otitidis following a dexamethasone intravitreal implant
JPWO2016072440A1 (ja) 眼科用水性組成物
JP6487609B1 (ja) 点眼剤
Tabbara et al. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%
JP4758893B2 (ja) キノロンを含む眼科用組成物及びその使用の方法
HK1178045A (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
HK1177887B (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
CN114129590B (zh) 一种眼用组合物及其制备方法与应用
Tabbara et al. Effects of fusidic acid on staphylococcal keratitis.
Booysen South African Guide to topical ophthalmic drugs
KR20150090045A (ko) 피나플록사신 현탁 조성물
US11672798B2 (en) Ciprofloxacin ophthalmic topical composition for treating ocular disease
AKANDA et al. Efficacy of Perioperative Oral Antibiotics in the Prevention of Acute Infective Endophthalmitis after SICS
JP2004049228A (ja) 麦粒腫の病態モデル動物およびその作製方法
Khuu et al. Contact Lens-Related Corneal Ulcer: A Teaching Case Report.
Esporcatte et al. Panoftalmite com celulite orbitária após implante de drenagem em glaucoma congênito
KR20110030824A (ko) 제미플록사신을 포함하는 안구 감염의 예방 또는 치료용 점안제
Pahuja et al. Endophthalmitis
Wittpenn Considerations in the Treatment of Ocular Inflammation: V. Infectious Conjunctivitis
HK1238174A1 (en) Ophthalmic aqueous composition

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees